Navigation Links
FDA Approves Novel Melanoma Drug
Date:8/17/2011

determine if a patient's melanoma cells have the BRAF V600E mutation. The first-of-a-kind test is called the cobas 4800 BRAF V600 Mutation Test.

"We now have the capability to analyze a patient's melanoma tumor for the genetic mutation BRAF and use the targeted treatment Zelboraf to attack the tumor, shrink it and stop the progression of this deadly disease," Pavlick said. "The drug comes in a simple pill form, taken twice a day."

According to the FDA, Zelboraf's approval came as part of an accelerated review program, and was based on a single international trial of 675 patients with late-stage melanoma with the BRAF V600E mutation who did not receive prior treatment. In the trial, patients received either Zelboraf or another cancer drug called dacarbazine. The median survival time after treatment was 8 months (64 percent still living) for patients in the dacarbazine group but has not been reached for patients in the Zelboraf group (77 percent still living), the agency said.

Still, not every person with melanoma will benefit from Zelboraf, and much more research is needed, the MRA's Selig said.

"While the entire melanoma community applauds the breakthrough exemplified by vemurafenib [Zelboraf], the data demonstrate that tumors have the ability to develop resistance to the drug, causing patients to relapse," she noted. "Additionally, because some patients with BRAF mutation do not respond to the drug and about half of patients do not have the mutation, finding additional new targets remains an ongoing urgent need."

The most common side effects among patients taking Zelboraf were joint pain, rash, hair loss, fatigue, nausea and sun-related skin sensitivity. About 26 percent of the patients taking Zelboraf developed cutaneous squamous cell carcinoma, the second most common form of nonmelanoma skin cancer. It was managed with surgery.

Patients who take Zelboraf should avoid sun exposure, the FDA said.

According to the American
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Approves Blood Thinner Brilinta for Heart Patients
2. FDA Approves Test That Spots Aggressive Breast Cancer
3. FDA Approves Test That Spots HER2-Positive Breast Cancers
4. FDA Approves Another New Drug to Fight Hepatitis C
5. FDA approves new drug for advanced melanoma
6. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
7. FDA Approves 1st New Lupus Drug in More Than 50 Years
8. FDA Approves First 3D Mammogram Device
9. FDA Approves First Pacemaker Deemed Safe During MRIs
10. FDA Approves First Drug to Prevent Premature Births
11. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Novel Melanoma Drug
(Date:5/5/2015)... Jacksonville, Fla. (PRWEB) May 05, 2015 ... from the Commission on Cancer (CoC) of the American ... a cancer program must meet more than 30 Commission ... years through a survey process, and maintain levels of ... , When patients choose to seek care locally ...
(Date:5/5/2015)... Nutritional science and medical research has enabled ... health conditions and illnesses linked to carrying excess weight. ... eating methods to rid the body of dangerous toxins, ... fast and processed foods. Patients find the company’s ... report feeling better and losing excess fat within days. ...
(Date:5/5/2015)... 05, 2015 In a April 25, 2015, ... Herald-Times , the Missouri State Highway Patrol (MSHP) announced that ... or use for the second year in a row. ... FBI, reported 1,469 incidents in 2014 alone, around 15% of ... 2% of the US Population calls Indiana home, according to ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
... Giving shot 2 weeks earlier reduces the time babies ... 3 (HealthDay News) -- Giving infants a routine pertussis ... prevent at least 1,236 cases of pertussis, 898 hospitalizations ... a new study finds. , Researchers at Wake Forest ...
... the top 100, EL SEGUNDO, Calif., Nov. ... care services for those diagnosed with chronic kidney,failure ... 100 of Modern Healthcare,s,Best Places to Work in ... only nationwide healthcare services company on the list., ...
... Inc. and to Continue,Trading on NASDAQ under ... Cornerstone BioPharma,Holdings, Inc., a specialty pharmaceutical company ... respiratory disorders,today announced the completion of its ... biopharmaceutical company focused on,developing and commercializing innovative ...
... 3 Avineuro Pharmaceuticals, Inc.,announced today the completion ... for treatment of Alzheimer,s disease. These studies,demonstrate that ... it has a,favorable pharmacokinetic profile. Based on these ... AVN-101 into clinical,trials in Q1 2009. Results of ...
... adoption of daily home therapy continues to grow; ... LAWRENCE, Mass., Nov. 3 NxStage Medical, Inc.,(Nasdaq: ... dialysis products,today announced that 3,000 end-stage renal disease ... its NxStage(R) System One(TM), the,first truly portable home ...
... a leading provider of laser vision correction services under ... team will present at the Rodman & Renshaw 10th ... a.m. Eastern time. The,conference is being held at The ... A live and archived webcast of the event will ...
Cached Medicine News:Health News:Earlier Vaccination Could Cut Whooping Cough Deaths 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 2Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 3Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 4Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 5Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 2Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 3Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 4
(Date:5/5/2015)... 2015 Research and Markets ( ... "Electro Surgical Market" report to their ... expected to achieve a CAGR of 7% for ... benefits for patients as well as surgeons such ... visible marks, bleeding control and improved accuracy are ...
(Date:5/5/2015)... -- IQPC,s 19 th Software Design for Medical Devices ... Summit Mr. Phani Bidarahalli , GM & Head of ... expert speaker faculty including senior executive from GE Healthcare, Philips ... The Hotel Kabuki in San Francisco . ... the event website, which can be accessed by visiting ...
(Date:5/5/2015)... Lymphatic pump treatment (LPT) shows promise in managing pneumonia ... study published in The Journal of the American ... on infected rats three times a day followed by ... pneumonia. After 96 hours, over 60 percent of the ... of rats who received levofloxacin alone. Commonly ...
Breaking Medicine Technology:Global Electro Surgical Market 2015 2Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 2Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 2
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Refresh Contacts provides moisturizing relief from dryness and irritation associated with lens wear....
Specially formulated to lubricate and moisten lenses to help relieve irritation and dryness....
... Renu Multiplus preservative free ... and moisturize your eyes while ... The gentle preservative free formula ... may be sensitive to preservatives ...
Medicine Products: